Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles Post author: Post published:April 5, 2024 Post category:uncategorized Recombinant adeno-associated virus (rAAV)-based genetic applications to treat human diseases. You Might Also Like FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer August 5, 2024 American Heart Association launches initiative to tackle recurrent pericarditis June 17, 2024 Weekend warrior exercise approach comparable to regular exercise for weight loss February 20, 2024